Table 1.

Demographic characteristics; NoT, no treatment; AR, antiresorptive treatment; ROMO, treatment with romosozumab; PBST, prior bone-specific treatment; ANOVA, analysis of variance, ^aNoT vs. AR, lowest spine = lowest lumbar spine value of at least two adjacent vertebrae (L₁–L₄), avg. total femur = average value of the left and right femur, total spine = average BMD of L₁–L₄

	NoT	AR	ROMO	ANOVA
n = 33	n = 12	n = 11	n = 10
Age [years]	52.2 ± 9.3	63.6 ± 9.4	54.8 ± 7.5	p = 0.011a
Menopause [years]	49.9 ± 1.4	50.1 ± 3.7	50.0 ± 3.2	NS
BMI [kg/m2]	24.2 ± 6.2	23.5 ± 2.8	22.7 ± 2.5	NS
Baseline BMD
Total spine [gHA/cm2]	0.87 ± 0.09	0.87 ± 0.14	0.75 ± 0.08	NS
Avg. total femur [gHA/cm2]	0.79 ± 0.08	0.72 ± 0.12	0.72 ± 0.12	NS
Baseline T-score
Lowest spine	−3.0 ± 0.5	−2.8 ± 1.2	−3.9 ± 1.0	NS
Lowest total femur	−1.8 ± 0.6	−2.4 ± 1.0	−2.4 ± 1.0	NS
Genetic variant
LRP5	75%	63.6%	80%	NS
LRP6	8.3%	9.1%	10%	NS
WNT1	16.7%	27.3%	10%	NS
PBST	8.3%	63.4%	50%	p = 0.016a
Fractures
Vertebral	16.7%	72.3%	40%	p = 0.017a
Non-vertebral	75%	54.5%	50%	NS